Abstract Library

#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)

Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C,

Keywords: alkylating agents, pancreatic NET, re-challenge, chemotherapy,

#2904 Prognosis and Management of Advanced Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors (G3 NETs): A NET-CONNECT Study Performed in Four Expert Centers

Introduction: G3 NETs are rare tumors with poorly defined prognosis and management.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: de Mestier L, Lamarca A, Hernando-Cubero J, Alonso Gordoa T, Cros J,

Keywords: grade 3, prognosis, treatment, alkylating agents,

#1471 Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?

Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Marotta V

Authors: Marotta V, Malka D, Walter T, Do Cao C, Faggiano A,

Keywords: pancreatic neuroendocrine tumor, chemotherapy,

#1337 O6-Methylguanine DNA Methyltransferase (MGMT) Deficiency and Response to Aranoza-Based Therapy in Patients with Neuroendocrine Tumors

Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ. O6-methylguanine DNA methyltransferase (MGMT) is an enzyme implicated in chemotherapy resistance to alkylating agents and its low levels are associated with sensitivity to them.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Polozkova S, Stepanova E, Delektorskaya V, Kozlov N, Gorbunova V,

Keywords: aranoza, MGMT, chemotherapy, NETs,

#1067 Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status?

Introduction: Alkylating agents are the backbone chemotherapy in neuroendocrine tumors (NET). However, gemcitabine associated to oxaliplatine (gemox) has showed interesting activity in a small study.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Dussol A, Joly M, Hervieu V, Forestier J, Lombard-Bohas C,

Keywords: gemox, alkylating agent, MGMT,